EP1408956A1 - Utilisation de sels metalliques pour stabiliser des compositions a base de taxane - Google Patents

Utilisation de sels metalliques pour stabiliser des compositions a base de taxane

Info

Publication number
EP1408956A1
EP1408956A1 EP01920712A EP01920712A EP1408956A1 EP 1408956 A1 EP1408956 A1 EP 1408956A1 EP 01920712 A EP01920712 A EP 01920712A EP 01920712 A EP01920712 A EP 01920712A EP 1408956 A1 EP1408956 A1 EP 1408956A1
Authority
EP
European Patent Office
Prior art keywords
acid
composition
carrier
taxane
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01920712A
Other languages
German (de)
English (en)
Inventor
Kai Zhang
Gregory A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
Baker Cummins Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharmaceuticals Inc filed Critical Baker Cummins Pharmaceuticals Inc
Publication of EP1408956A1 publication Critical patent/EP1408956A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • TWEEN TM polyoxyethylated sorbitan esters ICI Wilmington, DE
  • SOFTIGEN TM polyethylene glycol esters of caprylic and capric acids H ⁇ ls AG
  • modified castor oils including polyoxyethylated or hydrogenated castor oils (such as CREMOPHOR TM EL, EP-P or RH 40) (BASF, Mt.
  • the surface absorption for pinewood charcoal is 1,000 m 2 /g and 650 m 2 /g for peat charcoal.
  • the activated charcoal has a surface area ranging from about 500 to about 1300 m /g (including sub-ranges thereof), and preferably a median surface area range of about 900 m /g.
  • taxane carriers such as castor oils with charcoal is described in International patent publication WO 00023070.
  • Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 Ed., McGraw Hill Companies Inc., New York (1996). Standard reference works setting forth the general principles of modern pharmaceutics (Remington's Pharmaceutical Sciences, 18 th Ed., Gennaro, Mack Publishing Co., Easton, PA (1990) and Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins (1995)).
  • the following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature.
  • EXAMPLE 1 Stability Tests of Paclitaxel in Pretreated Cremophor EL The stabilizing effect of coordinating metal salts, such as zinc, copper and ferrous sulfate or gluconate, on paclitaxel in an EtOH/EL (50:50) formulation (6 mg/mL) was examined. Salt columns were used to treat Cremophor EL before being added to paclitaxel formulations, which was then analyzed after being subjected to stress (24 hours at 80°C).
  • coordinating metal salts such as zinc, copper and ferrous sulfate or gluconate
  • Paclitaxel composition containing Cu 2+ Gluconate, Fe 2+ Gluconate, Ca 2+ Ascorbate, FeSO , A.A 6-Palmitate, or HOCH 2 SO 2 Na was prepared in the same way.
  • the paclitaxel samples and the control were subjected to 80°C for 24 hours. Then the paclitaxel degradation was tested.
  • the paclitaxel stability tests results are shown in Table 2.
  • the paclitaxel formulation containing Ascorbyl 6-Palmitate was prepared by adding Ascorbyl 6-Palmitate to the control formulation.
  • the stability test results were listed in Table 4.
  • Ascorbyl palmitate (5 mg) added as an ethanol solution to the paclitaxel formulation.
  • the data in Table 4 show that in the presence of Ascorbyl 6-Palmitate, paclitaxel degradation is less than 1% after being exposed to a temperature of 80°C for 24 hours. In the absence of Ascorbyl 6-Palmitate, paclitaxel degradation in the formulation is more than 34% after being exposed to the same condition.
  • Cremophor El (-400 mL) was pumped through a steel column containing activated charcoal (34 g) at a flow rate of approximately 0.2 mlVmin. The initial eluate (-20 mL) was discarded and the successive fraction (-45 mL) was collected and subsequently passed through a second steel column containing FeSO (18 g). The initial eluate was discarded (-20 mL) and the remainder of material was used to prepare the Paclitaxel formulation for stability analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions contenant un taxane, un excipient, et un sel métallique d'un acide. L'invention concerne également des procédés permettant de stabiliser des compositions de taxane/excipient, et de réduire la dégradation des taxanes, par exemple, pendant un stockage. Ces procédés impliquent l'incorporation du sel métallique dans la composition de taxane, ou le préchauffage de l'excipient avec ledit sel métallique, éventuellement associé à d'autres prétraitements.
EP01920712A 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane Withdrawn EP1408956A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19180200P 2000-03-24 2000-03-24
US191802P 2000-03-24
PCT/US2001/009416 WO2001072300A1 (fr) 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane

Publications (1)

Publication Number Publication Date
EP1408956A1 true EP1408956A1 (fr) 2004-04-21

Family

ID=22706985

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01920699A Withdrawn EP1315484A1 (fr) 2000-03-24 2001-03-23 Compositions a base de taxane et procedes d'utilisation
EP01920712A Withdrawn EP1408956A1 (fr) 2000-03-24 2001-03-23 Utilisation de sels metalliques pour stabiliser des compositions a base de taxane

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01920699A Withdrawn EP1315484A1 (fr) 2000-03-24 2001-03-23 Compositions a base de taxane et procedes d'utilisation

Country Status (7)

Country Link
EP (2) EP1315484A1 (fr)
JP (2) JP2003528141A (fr)
KR (2) KR20030019327A (fr)
AR (2) AR027715A1 (fr)
AU (2) AU2001247739A1 (fr)
CA (2) CA2404370A1 (fr)
WO (2) WO2001072300A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710195B2 (en) * 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
AU2002360816A1 (en) * 2001-12-28 2003-07-24 Ivax Research, Inc. Taxane based compositions and methods of use
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
BRPI0513673B8 (pt) * 2004-08-03 2021-07-27 Vital Health Sciences Pty Ltd método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
EP1690551A3 (fr) 2005-02-10 2006-10-18 Sindan Pharma Srl Purification d'un tenside par ultrafiltration
AU2006212177A1 (en) * 2005-02-10 2006-08-17 Sindan Pharma Srl Method of purifying a surfactant by ultrafiltration
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
JP2008543789A (ja) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー ドセタキセルの液体薬学的処方物
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
EP2531047B1 (fr) 2010-02-05 2024-11-13 Phosphagenics Limited Vecteur comprenant du phosphate de tocophéryle non neutralisé
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
ES2718090T3 (es) * 2010-11-08 2019-06-27 Cadila Pharmaceuticals Ltd Composición farmacéutica de taxoides
WO2012122586A1 (fr) 2011-03-15 2012-09-20 Phosphagenics Limited Nouvelle composition
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
CN110585189B (zh) * 2019-09-05 2022-12-30 广东艾时代生物科技有限责任公司 三尖杉宁碱在制备治疗疟疾药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
CN1225262A (zh) * 1998-12-09 1999-08-11 延边香料研究所 一种含有紫杉醇的抗癌药物
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0172300A1 *

Also Published As

Publication number Publication date
JP2003528141A (ja) 2003-09-24
AU2001247739A1 (en) 2001-10-08
CA2404370A1 (fr) 2001-10-04
AR027714A1 (es) 2003-04-09
WO2001072299A1 (fr) 2001-10-04
AU2001247726A1 (en) 2001-10-08
AR027715A1 (es) 2003-04-09
JP2003528142A (ja) 2003-09-24
CA2404374A1 (fr) 2001-10-04
EP1315484A1 (fr) 2003-06-04
WO2001072300A1 (fr) 2001-10-04
KR20030019328A (ko) 2003-03-06
KR20030019327A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
WO2001072300A1 (fr) Utilisation de sels metalliques pour stabiliser des compositions a base de taxane
JP2595458B2 (ja) タキサン類の誘導体を基とする新規組成物
JP2618596B2 (ja) タキサン類の誘導体を基とする新規組成物
CN1169525C (zh) 紫杉烷的药物制剂
JP2003526612A (ja) タキソイド抗新生物薬を含有する安定化した注射可能な医薬組成物
US20200237707A1 (en) Pharmaceutical composition for oral administration comprising taxane
EP1978953A1 (fr) Compositions pharmaceutiques contenant du docétaxel et un inhibiteur de dégradation et leur procédé d'obtention
JP2003503339A (ja) 抗癌剤を含有する自己乳化システム
AU2007246077A1 (en) Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
WO2003057208A1 (fr) Compositions a base de taxane et procedes d'utilisation
EP2034957B1 (fr) Composition pharmaceutique pour administration orale
US20050016926A1 (en) Stabilized formulation
US20060058541A1 (en) Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
CA2532110A1 (fr) Procede de purification de solvants non ioniques pour preparations pharmaceutiques injectables stabilisees
AU2004203394A1 (en) Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041201